PT  - JOURNAL ARTICLE
AU  - ,
AU  - ,
AU  - ,
AU  - Zarychanski, Ryan
TI  - Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 – Preliminary Report
AID  - 10.1101/2021.03.10.21252749
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.10.21252749
4099  - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21252749.short
4100  - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21252749.full
AB  - Background Thrombosis may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic anticoagulation would improve outcomes in critically ill patients with Covid-19.Methods We conducted an open-label, adaptive, multiplatform, randomized, clinical trial. Patients with severe Covid-19, defined as the requirement for organ support with high flow nasal cannula, non-invasive ventilation, invasive ventilation, vasopressors, or inotropes, were randomized to receive therapeutic anticoagulation with heparin or pharmacological thromboprophylaxis as per local usual care. The primary outcome was an ordinal scale combining in-hospital mortality (assigned –1) and days free of organ support to day 21.Results Therapeutic anticoagulation met the pre-defined criteria for futility in patients with severe Covid-19. The primary outcome was available for 1,074 participants (529 randomized to therapeutic anticoagulation and 545 randomized to usual care pharmacological thromboprophylaxis). Median organ support-free days were 3 days (interquartile range –1, 16) in patients assigned to therapeutic anticoagulation and 5 days (interquartile range –1, 16) in patients assigned to usual care pharmacological thromboprophylaxis (adjusted odds ratio 0.87, 95% credible interval (CrI) 0.70-1.08, posterior probability of futility [odds ratio<1.2] 99.8%). Hospital survival was comparable between groups (64.3% vs. 65.3%, adjusted odds ratio 0.88, 95% CrI 0.67-1.16). Major bleeding occurred in 3.1% of patients assigned to therapeutic anticoagulation and 2.4% of patients assigned to usual care pharmacological thromboprophylaxis.Conclusions In patients with severe Covid-19, therapeutic anticoagulation did not improve hospital survival or days free of organ support compared to usual care pharmacological thromboprophylaxis.Trial registration numbers NCT02735707, NCT04505774, NCT04359277, NCT04372589Competing Interest StatementGrant funding for research. All authors have completed the ICMJE uniform disclosure form and declare: Dr. Zarychanski reports grants from Canadian Institutes of Health Research, grants from LifeArc Foundation, grants from Research Manitoba, grants from Peter Munk Cardiac Centre, grants from Thistledown Foundation, grants from National Institutes of Health, during the conduct of the study.Clinical TrialNCT02735707, NCT04505774, NCT04359277, NCT04372589Funding StatementREMAP-CAP: Supported by the European Union through FP7-HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium (602525), and Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium (101003589) and by the Australian National Health and Medical Research Council (APP1101719), the Health Research Council of New Zealand (16/631), a Canadian Institutes of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant (158584), the U.K. NIHR and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Breast Cancer Research Foundation, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, Amgen, Eisai, the Global Coalition for Adaptive Research, and the Wellcome Trust Innovations Project (215522). Dr. Gordon is funded by an NIHR Research Professorship (RP-2015-06-18), and Dr. Shankar-Hari by an NIHR Clinician Scientist Fellowship (CS-2016-16-011). The ATTACC platform was supported by grants from the Canadian Institutes of Health Research, LifeArc Foundation, Thistledown Foundation, Research Manitoba, Ontario Ministry of Health, and the Peter Munk Cardiac Centre. The ACTIV-4a platform was sponsored by the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD and administered through OTA-20-011. Disclaimer: The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service (UK), the National Institute for Health Research (UK), the Department of Health and Social Care (UK), or of the National Institutes of Health (USA). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics and regulatory approval were obtained at each of the participating centres in the Multiplatform trial. Ethical oversight and approval for each platform were provided by the institutional review boards of Monash University, Australia (REMAP-CAP), New York University and the Western Institutional Review Board, United States (ACTIV-4a), and the University of Manitoba, Winnipeg, Canada (ATTACC).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is not available